» Articles » PMID: 12593883

Valuing the Benefits and Costs of Health Care Programmes: Where's the 'extra' in Extra-welfarism?

Overview
Journal Soc Sci Med
Date 2003 Feb 21
PMID 12593883
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

The application of Sen's notion of capabilities to problems of the allocation of resources to health in the form of an extra-welfarist framework underlies the justification of quality adjusted life years (QALYs) as the method for valuing the benefits of health care. In this paper we critically appraise this application from both conceptual and empirical perspectives. We show that the alleged limitations of the welfarist approach are essentially limitations in its application, not in the capacity of the approach to accommodate the concerns of extra-welfarists. Moreover, the arguments used to justify the application of the extra-welfarist framework are essentially welfarist. We demonstrate that the methods used to measure QALYs share their basic theoretical roots with welfarist valuation methods, such as willingness to pay (WTP). Although QALYs and WTP share many challenges, we argue that WTP provides a method which performs better with respect to those challenges. In the context of evaluating alternative allocations of health care resources we are left asking what is 'extra' in extra-welfarism?

Citing Articles

Expanding health technology assessment towards broader value: Ireland as a case study.

Kinchin I, Walshe V, Normand C, Coast J, Elliott R, Kroll T Int J Technol Assess Health Care. 2023; 39(1):e26.

PMID: 37129030 PMC: 11569971. DOI: 10.1017/S0266462323000235.


Economic model of community-based falls prevention: seeking methodological solutions in evaluating the efficiency and equity of UK guideline recommendations.

Kwon J, Squires H, Young T BMC Geriatr. 2023; 23(1):187.

PMID: 36997884 PMC: 10061399. DOI: 10.1186/s12877-023-03916-z.


Conceptualising 'Benefits Beyond Health' in the Context of the Quality-Adjusted Life-Year: A Critical Interpretive Synthesis.

Engel L, Bryan S, Whitehurst D Pharmacoeconomics. 2021; 39(12):1383-1395.

PMID: 34423386 DOI: 10.1007/s40273-021-01074-x.


Health economic evaluation of gene replacement therapies: methodological issues and recommendations.

Aballea S, Thokagevistk K, Velikanova R, Simoens S, Annemans L, Antonanzas F J Mark Access Health Policy. 2020; 8(1):1822666.

PMID: 33144927 PMC: 7580851. DOI: 10.1080/20016689.2020.1822666.


Contingent Valuation Studies in Orthopaedic Surgery: A Health Economic Review.

Nwachukwu B, Eliasberg C, Hamid K, Fu M, Bach B, Allen A HSS J. 2018; 14(3):314-321.

PMID: 30258339 PMC: 6148581. DOI: 10.1007/s11420-018-9610-z.